| 4R, symptom screening only | 4R, Subclinical TB screening, same access | 4R, Subclinical TB screening, 20% reduced access | 6H, symptom screening only | 6H, Subclinical TB screening, same access | 6H, Subclinical TB screening, 20% reduced access |
---|---|---|---|---|---|---|
PWH cohort | ||||||
 Expected cases of active TB without TPT | 71 | 71 | 71 | 71 | 71 | 71 |
 Expected cases of active TB with TPT # | 25 | 16 | 27 | 33 | 20 | 31 |
 Net change in total active TB cases (versus no TPT) a | −45 | −55 | −44 | −37 | −51 | −41 |
 Net change in INH monoresistant cases (versus no TPT) | −3 | −2.9 | − 2.3 | 6.2 | −0.48 | − 0.38 |
 Net change in RIF monoresistant cases (versus no TPT) | 3 | 0.3 | 0.24 | −0.23 | −0.11 | − 0.09 |
 Net change in MDR cases (versus no TPT) | 0.63 | −0.56 | −0.45 | 0.18 | −0.59 | − 0.47 |
 Net change in total DR cases (versus no TPT) | −0.85 | −1.5 | − 1.2 | 1.1 | − 0.69 | − 0.55 |
 Symptomatic TB cases averted per RR/MDR added (vs no TPT) | 12 | b | b | b | b | b |
 INH monoresistance averted per RR/MDR added (vs no TPT) | 0.78 | b | b | b | b | b |
 Symptomatic TB cases averted per RR/MDR added (vs 6H) | 2 | 7.2 | 7.2 | NA | NA | NA |
 INH monoresistance averted per RR/MDR added (vs 6H) | 2.3 | 4 | 4 | NA | NA | NA |
Household contact cohort | ||||||
 Expected cases of active TB without TPT | 25 | 25 | 25 | 25 | 25 | 25 |
 Expected cases of active TB with TPT # | 7.8 | 6.8 | 10 | 12 | 10 | 13 |
 Net change in total active TB cases (versus no TPT) a | −17 | −18 | −15 | −13 | −15 | −12 |
 Net change in INH monoresistant cases (versus no TPT) | −1.6 | − 1.6 | −1.3 | 0.84 | −0.02 | −0.02 |
 Net change in RIF monoresistant cases (versus no TPT) | 0.39 | 0.09 | 0.07 | −0.06 | −0.05 | − 0.04 |
 Net change in MDR cases (versus no TPT) | 0.02 | −0.1 | −0.08 | 0 | −0.06 | − 0.05 |
 Net change in total DR cases (versus no TPT) | −0.56 | − 0.56 | −0.44 | 0.11 | −0.09 | − 0.07 |
 Symptomatic TB cases averted per RR/MDR added (vs no TPT) | 37 | b | b | b | b | b |
 INH monoresistance averted per RR/MDR added (vs no TPT) | 3.5 | b | b | b | b | b |
 Symptomatic TB cases averted per RR/MDR added (vs 6H) | 7.2 | 24 | 24 | NA | NA | NA |
 INH monoresistance averted per RR/MDR added (vs 6H) | 5 | 13 | 13 | NA | NA | NA |